Log in with your email address username.

×

[Correspondence] Reporting of immune checkpoint inhibitor-associated myocarditis – Authors’ reply

We thank Sadeer G Al-Kindi and Guilherme H Oliveira for their Correspondence, and we completely agree with the use of multiple databases to verify and validate our findings on fatalities linked with immune checkpoint inhibitor-associated myocarditis. Their use of the large US Food and Drug Administration database and incorporation of demographic features is commendable and provides additional evidence showing the fulminant and unpredictable nature of immune checkpoint inhibitor-associated myocarditis.

email